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and TCD-BM in absence of FLU (P  .01); recipient CMV
seronegative status (93% vs 69%, P  .02); HLA matched
donor-recipient pair (94% vs 69%, P  .01); negative transfu-
sion history (100% vs 83%, P  .05), and use of FLU in the
preparative regimen (94% vs 69% ,P  .01). Disease status at
HCT, androgen use, number of malformations, recipient age
and gender, mosaicism, and history of prior infections did not
have a demonstrable effect on neutrophil recovery. In multivar-
iate analysis, factors associated with improved neutrophil recov-
ery were CMV seronegative serostatus, HLA matched donor-
recipient pair and use of FLU (Table 1). Similarly, incidence of
platelet recovery (	20,000/uL) was signiﬁcantly higher in CMV
negative recipients (Relative Risk [RR] 2.46, 95% CI 1.16–5.22,
P  .02), HLA matched HSC (RR 3.1, 95% CI 1.39–6.82, P 
.01), and FLU (RR 10.8, 95% CI 2.82–41.3, P  .01). In
summary, hematopoietic recovery after AD HSCT in FA pa-
tients following FLU containing preparative regimens are com-
parable to those of HLA matched sibling donor BM recipients.
Therefore signiﬁcant practice changes should be considered
such as the use of a FLU containing preparative regimen,
particularly in the setting of TCD.
Table 1. Cox Regression on Primary Neutrophil Engraftment
Factors
Relative Risk
(95% CI) P-value
Model (X2  28.8, P < .01)
Recipient CMV
Positive* 1
Negative 1.95 (1.13–3.35) .02
HLA match
Mismatch* 1
Match 2.70 (1.59–4.60) .01
FLU
No* 1
Yes 2.10 (1.22–3.63) .01
*Note: reference category.
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LACK OF T CELL ALLOREACTIVITY TO CORD BLOOD MONONUCLEAR
CELLS
Chunduri, S., Mahmud, D., Abbasian, J., Rondelli, D. University of
Illinois at Chicago, Chicago, IL.
Transplantation of HLA-mismatched cord blood (CB) nucleated
cells has limited risk of graft rejection and severe acute graft-
versus-host disease. This may depend on naı¨ve T cells not yet
exposed to many antigens and/or on immature antigen-presenting
cells (APC) not delivering appropriate signals to allogeneic T cells.
In order to test the APC activity of human circulating CB cells in
vitro, we initially used irradiated CB mononuclear cells (MNC) or
immunomagnetically selected CD34 cells, CD133 cells, or
CD14 monocytes to stimulate the proliferative response of in-
compatible blood T cells in mixed leukocyte culture (MLC). CB
MNC failed to induce allogeneic T cell proliferation, while
CD34 and CD133 progenitors or CD14 monocytes induced
potent T cell alloresponses. Nevertheless, since allogeneic T cell
response was not restored after depletion of CD3 cells in the CB,
or the add-back of irradiated CB MNC to CD34 or CD14
stimulators inhibited allo-T cells, a direct suppressive effect of CB
MNC was excluded. Allogeneic peripheral blood cytotoxic T-
lymphocyte (CTL) responses were not induced after 7 days of
stimulation with irradiated CB MNC, although after 4 weekly
rechallenges with CB MNC, on average a 23% lysis of antigen-
speciﬁc CB PHA-blasts was observed at the highest effector:target
ratio (50:1). To test the tolerogenic potential of CB MNC, T cells
initially exposed to CB MNC were rechallenged in secondary
MLC with CB MNC, or CD34 cells, or monocyte-derived
dendritic cells (Mo-DC) generated in liquid culture with GM-CSF
and IL-4. Allogeneic T cells were still unresponsive upon rechal-
lenge with CB MNC, but proliferated upon 3 days of restimulation
with CD34 cells or Mo-DC from the same CB. These results
show an impaired allo-APC activity of CB MNC but not CB
CD34 cells, and suggest that although CB cells do not induce an
Ag-speciﬁc in vitro anergy, their weak APC activity may reduce the
risk of rejection in an HLA-mismatched stem cell transplant set-
ting. In addition, these ﬁndings may explain the initial engraftment
of two mismatched CB grafts, currently infused in CB transplant
protocols for adult patients.
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NO ASSOCIATION BETWEEN MIC-A POLYMORPHISM AND CLINICAL
OUTCOME AFTER ALLOGENEIC HSCT
Uzunel, M., Remberger, M. Karolinska Institutet, Clinical Immunology,
Stockholm, Sweden.
Background: MHC class I chain related molecule A (MIC-A)
shows homology with the classical HLA molecules. MIC-A is
polymorphic with more than 50 recognized alleles and is described
as a “marker of stress” since it is up-regulated on epithelial cells at
heat and virus infection. The presence of MIC-A antibodies in
patient sera has been associated with rejection after organ trans-
plantation. The signiﬁcance of MIC-A polymorphism in hemato-
poietic stem cell transplantation (HSCT) has not been studied. In
this study we wanted to see the degree of MIC-A mismatch be-
tween patients and donors and to investigate if the MIC-A geno-
type was associated with clinical outcome after HSCT. Materials
and Methods: For MIC-A genotyping, we performed PCR am-
pliﬁcation with allele-speciﬁc primers. A total of 248 leukemia
patients were included in the study. All received myeloablative
conditioning and GVHD prophylaxis consisted mainly of a com-
bination of cyclosporine A and methotrexate. In unrelated trans-
plants (149), both the patient and the donor were genotyped while
in sibling transplants (99) only the patient was genotyped. Results:
In unrelated transplants, 16 (11%) mismatches were found. Al-
though an increase in the incidence of chronic GVHD was found
among patients receiving a graft with MIC-A mismatch, there were
no signiﬁcant differences in leukemia free survival (LFS), trans-
plant related mortality (TRM) and GVHD between patients with
MIC-A match or mismatch. At the MIC-A allele level, no speciﬁc
allele was found to be associated with different clinical outcomes
after HSCT. Conclusion: MIC-A mismatch is a rare event in
HLA matched HSCT. Neither the MIC-A mismatch nor the
MIC-A alleles seem to have a major effect on the clinical outcome
after HSCT.
207
HSCT FROM PARTIALLY MATCHED ALTERNATIVE DONORS—A SINGLE
CENTRE EXPERIENCE
Vitek, A.1, Cetkovsky, P.1, Dobrovolna, M.1, Ivaskova, E.2,
Korinkova, P.1, Kovarova, P.1, Kupkova, L.2, Loudova, M.1,
Markova, M.1, Matejkova, E.1, Navratilova, J.3, Pitrova, H.3,
Pohlreich, D.1, Sajdova, J.1, Sponerova, D.1, Valkova, V.1, Vrana, M.1,
Vytiskova, J.1 1. Institute of Hematology and Blood Transfusion, Prague,
Czech Republic; 2. Czech Marrow Donor Registry, Prague, Czech Re-
public; 3. Czech National Marrow Donor Registry, Pilsen, Czech Re-
public.
Increased amount of indications for alloBMT is connected with
increased demand for donors. For approximately 30% of the pa-
tients is possible to ﬁnd HLA identical sibling, for another 70% of
the patients is necessary to obtain graft from alternative donors.
Because it can be difﬁcult or even impossible to ﬁnd fully matched
alternative donors, that means donors identical in all 10 HLA
antigens typed on HR level of A, B, C, DRB1, and DQB1 loci, we
must often accept donors with some mismatches. We performed
182 transplantations from alternative donors between 1991 and
2005. 89 were mismatched for one or more HLA alleles or anti-
gens. Twenty-nine patients were transplanted for AML, 26 for
CML, 12 for ALL, 10 for MDS, 4 for CLL, 3 for MMM, 2 for
NHL, 2 for HD, and 1 for MM. Half of these patients were
transplanted in advanced stage of the disease. In 80% of the
patients, ATG-Fresenius was used in conditioning and 17% of the
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